2026 Oklahoma Thoracic Oncology Conference

08:10 AM - 08:25 AM

Updates in perioperative treatment and Role of pathological response in early stage NSCLC – Chul Kim, MD

08:25 AM - 08:37 AM

Case-based Discussion – Amy Eberle, ARNP; Chul Kim, MD; Mohamed Hassan, MD; Matthew Reinersman, MD; Ranjit B Jasaraj, MD, MD; Raid Aljumaily, MD

08:38 AM - 08:50 AM

Case-based Discussion – Matthew Reinersman, MD; Chul Kim, MD; Mohamed Hassan, MD; Amy Eberle, ARNP; Nishant Rajendra Tiwari, MD; Raid Aljumaily, MD

08:50 AM - 09:05 AM

Amivantamab + Lazertinib vs Osimertinib: Combination Strategy vs Monotherapy for 1L EGFR exon 19/21 Mutations – Yasir Elamin, MD

09:05 AM - 09:15 AM

Panel Discussion – Paul El Tomb, MD, MD; Irim Yasin, MD, MD; Hassan Kaleem, MD; Jordan Malie Morton, MD; Yasir Elamin, MD; Jonathan Dowell, MD

09:15 AM - 09:30 AM

KRAS in NSCLC: Drive to targeted therapies-Current Insights – Nagla Abdel Karim, MD

09:30 AM - 09:40 AM

Lung Cancer Screening 3.0: AI, Risk Models, and Incidentalomas – Who Actually Belongs in the Scanner? – Nirmal Vimalchand Choradia, MD

09:40 AM - 09:50 AM

Risk-adapted screening, AI/radiomics, overdiagnosis, and incidental findings – Raymond Osarogiagbon, MD

09:50 AM - 10:00 AM

Panel Discussion – Mark Doescher, MD, MSPH; Nathaniel Moulton, MD; Raymond Osarogiagbon, MD; Houssein Youness, MD, MD; Nirmal Choradia, MD; Fawad Chaudry MD.,FCCP, MD

10:00 AM - 10:10 AM

Pro Position (MRD-positive = escalate (IO/TKI/ADC); MRD-negative = safely de-escalate) – Aadel Chaudhuri, MD

10:10 AM - 10:20 AM

Con Position (Assay variability, lead-time bias, lack of de-escalation data, risk of undertreating curable disease) – Amin Nassar, MD

10:20 AM - 10:25 AM

Audience Q&A with live polling

10:25 AM - 10:35 AM

Panel Discussion – Aadel Chaudhuri, MD; Amin Nassar, MD; L. Kyle Brett, MD

10:45 AM - 10:55 AM

HER2/HER3 and TROP2 ADCs in metastatic NSCLC efficacy vs ILD and other toxicities. – Ashtin Taylor, PharmD, PharmD

10:55 AM - 11:05 AM

Can Antibody–Drug Conjugates Replace Docetaxel in Non-Oncogene NSCLC in the Second Line? – Fawzi F Abu Rous, MD

11:05 AM - 11:15 AM

Case-based Discussion – Ajay Sheshadri, MD, MSCI; Maida Hafiz, MD; Fawzi F Abu Rous, MD; Joshua Glover, MD; Ashtin Taylor, PharmD, PharmD

11:15 AM - 11:25 AM

ADC and ICI lung toxicity : Are we getting any better in diagnosing or managing – Maida Hafiz, MD

11:25 AM - 11:35 AM

Pneumonitis on Novel ADCs from Phase 1 trials – Falah Fayaz, MD

11:35 AM - 11:50 AM

Discussion – Sarah K Hayward, PharmD; Maida Hafiz, MD; Debra Richardson, MD, Other; Ajay Sheshadri, MD, MSCI; Fawad Chaudry MD.,FCCP, MD

11:50 AM - 12:00 PM

Practice-changing data for the frontline setting and maintenance strategies in LS-SCLC & ES-SCLC; redefining SCLC care – Nagla Abdel Karim, MD

12:00 PM - 12:10 PM

Tarlatamab and Tarlatamab-Based Combinations in SCLC – Abdul Rafeh Naqash, MD

12:10 PM - 12:20 PM

Panel Discussion – Bilal Ahmad, MD, MD; Nagla Abdel Karim, MD; Muhammad Furqan, MD; Abdul Rafeh Naqash, MD